New Animal Models of Progressive Neurodegeneration: Tools for Developing Predictive Diagnostics and Identifying Presymptomatic Therapeutic Targets

  • Amber L. Marriott
  • Daphne A. Gill
  • Christopher A. Shaw
  • R. Andrew Tasker
Chapter
Part of the Advances in Predictive, Preventive and Personalised Medicine book series (APPPM, volume 2)

Abstract

Mental and neurological disorders are increasingly prevalent and constitute a major societal and economic burden worldwide. Many of these diseases and disorders are characterized by progressive deterioration over time that ultimately results in identifiable symptoms that in turn dictate therapy. Disease-specific symptoms, however, often occur late in the degenerative process. A better understanding of the presymptomatic events could allow for the development of new diagnostics and earlier interventions that could slow or stop the disease process. Such studies of progressive neurodegeneration require the use of animal models that are characterized by delayed or slowly developing disease phenotype(s). This brief review describes several examples of such animal models that have recently been developed with relevance to epilepsy, schizophrenia, autism spectrum disorders, amyotrophic lateral sclerosis and Parkinson’s disease.

Keywords

Autism Spectrum Disorder Autism Spectrum Disorder Temporal Lobe Epilepsy Kainic Acid Domoic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Amber Marriott is supported by a Canada Graduate Scholarship awarded through the Natural Sciences and Engineering Research Council of Canada and Daphne Gill is supported by a Post-doctoral fellowship from Innovation PEI. Research funding to the investigators was provided by an NINDS RO1 grant to CAS and an Atlantic Innovation Fund grant to RAT.

References

  1. 1.
    World Health Organization (2006) Neurology and public health. http://www.who.int/mental_health/neurology/en. Accessed 15 Mar 2012
  2. 2.
    OHSU Brain Institute (2010) Disease statistics. Oregon Health •& Science University. http://www.ohsu.edu/xd/health/services/brain/in-community/brain-awareness/brain-health/disease-statistics.cfm?WT_rank=1. Accessed 15 Mar 2012
  3. 3.
    Schulz JB, Falkenburger BH (2004) Neuronal pathology in Parkinson’s disease. Cell Tissue Res 318:135–137PubMedGoogle Scholar
  4. 4.
    Shaw CA, Hoglinger GU (2008) Neurodegenerative diseases: neurotoxins as sufficient etiological agents? Neuromol Med 10:1–9Google Scholar
  5. 5.
    Vorhees CV (1986) Principles of behavioural teratology. In: Riley EP, Vorhees CV (eds) Handbook of behavioural teratology. Plenum Press, New YorkGoogle Scholar
  6. 6.
    Kaufmann W (2000) Developmental neurotoxicity. In: Krinkle GJ (ed) The laboratory rat. Academic, LondonGoogle Scholar
  7. 7.
    Ben-Ari Y (2001) Developing networks play a similar melody. Trends Neurosci 24:353–360PubMedGoogle Scholar
  8. 8.
    Dobbing J, Smart JL (1974) Vulnerability of developing brain and behaviour. Br Med Bull 30:164–168PubMedGoogle Scholar
  9. 9.
    Murray CJL, Lopez AD (eds) (1994) Global comparative assessment in the health sector: disease burden, expenditures, and intervention packages. World Health Organization, GenevaGoogle Scholar
  10. 10.
    Engel J Jr, Schwartzkroin PA (2006) What should be modeled? In: Pitkanen A, Schwartzkroin PA, Moshe SL (eds) Models of seizures and epilepsy. Academic, LondonGoogle Scholar
  11. 11.
    Jefferys JGR (2003) Models and mechanisms of experimental epilepsies. Epilepsia 44:44–50PubMedGoogle Scholar
  12. 12.
    Pitkanen A, Schwartzkroin PA, Moshe SL (eds) (2006) Models of seizures and epilepsy. Academic Press, LondonGoogle Scholar
  13. 13.
    Cavalheiro EA, Silva DF, Turski WA, Calderazzo-Filho LS, Bortolotto ZA, Turski L (1987) The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Dev Brain Res 37:43–58Google Scholar
  14. 14.
    Stafstrom CE, Thompson JL, Holmes GL (1992) Kainic acid seizures in the developing brain: status epilepticus and spontaneous recurrent seizures. Brain Res Dev Brain Res 65:227–236PubMedGoogle Scholar
  15. 15.
    Stafstrom CE, Chronopoulos A, Thurber S, Thompson JL, Holmes GL (1993) Age-dependent cognitive and behavioral deficits after kainic acid-induced seizures. Epilepsia 34:420–432PubMedGoogle Scholar
  16. 16.
    Doucette TA, Strain SM, Allen GV, Ryan CL, Tasker RA (2000) Comparative behavioural toxicity of domoic acid and kainic acid in neonatal rats. Neurotox Teratol 22:863–869Google Scholar
  17. 17.
    Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL (1997) GABA-A, NMDA and AMPA receptors: a developmentally regulated ‘ménage a trois’. Trends Neurosci 20:523–529PubMedGoogle Scholar
  18. 18.
    Nitecka L, Tremblay E, Charton G, Bouillot JP, Berger ML, Ben-Ari Y (1984) Maturation of kainic acid seizure-brain damage syndrome in the rat. II. Histopathological sequelae. Neuroscience 13:1073–1094PubMedGoogle Scholar
  19. 19.
    Sperber EF, Haas KZ, Stanton PK, Moshé SL (1991) Resistance of the immature hippocampus to seizure-induced synaptic reorganization. Brain Res Dev Brain Res 60:88–93PubMedGoogle Scholar
  20. 20.
    Haas KZ, Sperber EF, Opanashuk LA, Stanton PK, Moshé SL (2001) Resistance of immature hippocampus to morphologic and physiologic alterations following status epilepticus or kindling. Hippocampus 11:615–625PubMedGoogle Scholar
  21. 21.
    Holmes GL, Sarkisian M, Ben-Ari Y, Chevassus-Au-Louis N (1999) Mossy fiber sprouting after recurrent seizures during early development in rats. J Comp Neurol 22:537–553Google Scholar
  22. 22.
    Liu Z, Yang Y, Silveira DC, Sarkisian MR, Tandon P, Huang LT, Stafstrom CE, Holmes GL (1999) Consequences of recurrent seizures during early brain development. Neuroscience 92:1443–1454PubMedGoogle Scholar
  23. 23.
    Galic MA, Riazi K, Heida JG, Mouihate A, Fournier NM, Spencer SJ, Kalynchuk LE, Teskey GC, Pittman QJ (2008) Postnatal inflammation increases seizure susceptibility in adult rats. J Neurosci 28:6904–6913PubMedGoogle Scholar
  24. 24.
    Galic MA, Riazi K, Henderson AK, Tsutsui S, Pittman QJ (2009) Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 36:343–351PubMedGoogle Scholar
  25. 25.
    Riazi K, Galic MA, Pittman QJ (2010) Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 89:34–42PubMedGoogle Scholar
  26. 26.
    Verdoorn TA, Johansen TH, Drejer J, Nielsen EO (1994) Selective block of recombinant GluR6 receptors by NS-102; a novel non-NMDA receptor antagonist. Eur J Pharmacol 269:43–49PubMedGoogle Scholar
  27. 27.
    Tasker RA, Strain SM, Drejer J (1996) Selective reduction in domoic acid toxicity in vivo by a novel non-N-methyl-D-aspartate receptor antagonist. Can J Physiol Pharmacol 74:1047–1054PubMedGoogle Scholar
  28. 28.
    Perl TM, Bedard L, Kosatsky T, Hockin JC, Todd EC, Remis RS (1990) An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 322:1775–1780PubMedGoogle Scholar
  29. 29.
    Teitelbaum J, Zatorre RJ, Carpenter S, Gendron D, Cashman NR (1990) Neurologic sequelae of domoic acid intoxication due to ingestion of contaminated mussels. N Engl J Med 322:1781–1787PubMedGoogle Scholar
  30. 30.
    Cendes F, Andermann F, Carpenter S, Zatorre RJ, Cashman NR (1995) Temporal lobe epilepsy caused by domoic acid intoxication: evidence for glutamate receptor-mediated excitotoxicity in humans. Ann Neurol 37:123–126PubMedGoogle Scholar
  31. 31.
    Doucette TA, Bernard PB, Yuill PC, Tasker RA, Ryan CL (2003) Low doses of non-NMDA glutamate receptor agonists alter neurobehavioural development in the rat. Neurotox Teratol 25:473–479Google Scholar
  32. 32.
    Doucette TA, Bernard PB, Husum H, Perry MA, Ryan CL, Tasker RA (2004) Low doses of domoic acid during postnatal development produce permanent changes in rat behaviour and hippocampal morphology. Neurotox Res 6:555–563PubMedGoogle Scholar
  33. 33.
    Bernard PB, Macdonald DS, Gill DA, Ryan CL, Tasker RA (2007) Hippocampal mossy fiber sprouting and elevated trkB receptor expression following systemic administration of low dose domoic acid during neonatal development. Hippocampus 17:1121–1133PubMedGoogle Scholar
  34. 34.
    MacDonald DS, Bernard PB, Ramsay Gill DA, Tasker RA (2008) Progressive changes in hippocampal cytoarchitecture in a non-convulsive developmental model of TLE. Program No. 449.8 Neuroscience Meeting Planner. Washington, DC: Society for NeuroscienceGoogle Scholar
  35. 35.
    Gill DA, Bastlund JF, Anderson NJ, Tasker RA (2009) Reductions in paradoxical sleep time in adult rats treated neonatally with low dose domoic acid. Behav Brain Res 205:564–569PubMedGoogle Scholar
  36. 36.
    Gill DA, Ramsay SL, Tasker RA (2010) Selective reductions in subpopulations of GABAergic neurons in a developmental rat model of epilepsy. Brain Res 1331:114–123PubMedGoogle Scholar
  37. 37.
    Tamminga CA, Holcomb HH (2005) Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10:27–39PubMedGoogle Scholar
  38. 38.
    Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia “just the facts” 4: clinical features and conceptualization. Schizophr Res 110:1–23PubMedGoogle Scholar
  39. 39.
    Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122–1129PubMedGoogle Scholar
  40. 40.
    Caldwell CB, Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16:571–589PubMedGoogle Scholar
  41. 41.
    Radomsky ED, Haas GL, Mann JJ, Sweeney JA (1999) Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am J Psychiatry 156:1590–1595PubMedGoogle Scholar
  42. 42.
    Valevski A, Zalsman G, Tsafrir S, Lipschitz-Elhawi R, Weizman A, Shohat T (2012) Rate of readmission and mortality risks of schizophrenia patients who were discharged against medical advice. Eur Psychiatry 27:496–499Google Scholar
  43. 43.
    Rapoport JL, Addington AM, Frangou S (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434–449PubMedGoogle Scholar
  44. 44.
    Mednick SA, Machon RA, Huttunen MO (1998) Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45:189–192Google Scholar
  45. 45.
    Cannon M, Jones PB, Murray RM (2002) Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159:1080–1092PubMedGoogle Scholar
  46. 46.
    Geddes JR, Verdoux H, Takei N, Lawrie SM, Bovet P, Eagles JM, Heun R, McCreadie RG, McNeil TF, O'Callaghan E, Stöber G, Willinger U, Murray RM (1999) Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis. Schizophr Bull 25:413–423PubMedGoogle Scholar
  47. 47.
    Fiore M, Grace AA, Korf J, Stampachiacchiere B, Aloe L (2004) Impaired brain development in the rat following prenatal exposure to methylazoxymethanol acetate at gestational day 17 and neurotrophin distribution. Neuroreport 15:1791–1795PubMedGoogle Scholar
  48. 48.
    Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897PubMedGoogle Scholar
  49. 49.
    Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877–892PubMedGoogle Scholar
  50. 50.
    Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O'Neill FA, Walsh D, Kendler KS (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71:337–348PubMedGoogle Scholar
  51. 51.
    Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98:6917–6922PubMedGoogle Scholar
  52. 52.
    Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, St Clair DM, Muir WJ, Blackwood DH, Porteous DJ (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9:1415–1423PubMedGoogle Scholar
  53. 53.
    O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL (2007) Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Behav Rev 31:60–78Google Scholar
  54. 54.
    Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67–75PubMedGoogle Scholar
  55. 55.
    Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 122:35–43Google Scholar
  56. 56.
    Grecksch G, Bernstein HG, Becker A, Höllt V, Bogerts B (1999) Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20:525–532PubMedGoogle Scholar
  57. 57.
    Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002) Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27:47–54PubMedGoogle Scholar
  58. 58.
    Brady AM (2009) Neonatal ventral hippocampal lesions disrupt set-shifting ability in adult rats. Behav Brain Res 205:294–298PubMedGoogle Scholar
  59. 59.
    Becker A, Grecksch G, Bernstein HG, Höllt V, Bogerts B (1999) Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 144:333–338Google Scholar
  60. 60.
    Brady AM, Saul RD, Wiest MK (2010) Selective deficits in spatial working memory in the neonatal ventral hippocampal lesion rat model of schizophrenia. Neuropharmacology 59:605–611PubMedGoogle Scholar
  61. 61.
    Alquicer G, Silva-Gómez AB, Peralta F, Flores G (2004) Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci 22:103–111PubMedGoogle Scholar
  62. 62.
    Becker A, Grecksch G (2003) Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus. Pharmacol Biochem Behav 76:1–8PubMedGoogle Scholar
  63. 63.
    Daenen EW, Wolterink G, Van Ree JM (2003) Hyperresponsiveness to phencyclidine in animals lesioned in the amygdala on day 7 of life. Implications for an animal model of schizophrenia. Eur Neuropsychopharmacol 13:273–279PubMedGoogle Scholar
  64. 64.
    Miner LA, Ostrander M, Sarter M (1997) Effects of ibotenic acid-induced loss of neurons in the medial prefrontal cortex of rats on behavioral vigilance: evidence for executive dysfunction. J Psychopharmacol 11:169–178PubMedGoogle Scholar
  65. 65.
    Brown AS, Derkits EJ (2010) Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167:261–280PubMedGoogle Scholar
  66. 66.
    Zuckerman L, Weiner I (2005) Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39:311–323PubMedGoogle Scholar
  67. 67.
    Wolff AR, Bilkey DK (2008) Immune activation during mid-gestation disrupts sensorimotor gating in rat offspring. Behav Brain Res 190:156–159PubMedGoogle Scholar
  68. 68.
    Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M (2006) Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59:546–554PubMedGoogle Scholar
  69. 69.
    Zuckerman L, Weiner I (2003) Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) 169:308–313Google Scholar
  70. 70.
    Zuckerman L, Rehavi M, Nachman R, Weiner I (2003) Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28:1778–1789PubMedGoogle Scholar
  71. 71.
    Shi L, Fatemi SH, Sidwell RW, Patterson PH (2003) Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23:297–302PubMedGoogle Scholar
  72. 72.
    Meyer U, Feldon J, Schedlowski M, Yee BK (2005) Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29:913–94773PubMedGoogle Scholar
  73. 73.
    Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, Yee BK, Feldon J (2006) The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioural pathology. J Neurosci 26:4752–4762PubMedGoogle Scholar
  74. 74.
    Meyer U, Engler A, Weber L, Schedlowski M, Feldon J (2008) Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 154:701–709PubMedGoogle Scholar
  75. 75.
    Harris LW, Sharp T, Gartlon J, Jones DN, Harrison PJ (2003) Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 18:1706–1710PubMedGoogle Scholar
  76. 76.
    Kawabe K, Iwasaki T, Ichitani Y (2007) Repeated treatment with N-methyl-d-aspartate antagonists in neonatal, but not adult, rats causes long-term deficits of radial-arm maze learning. Brain Res 1169:77–86PubMedGoogle Scholar
  77. 77.
    Montgomery EM, Bardgett ME, Lall B, Csernansky CA, Csernansky JG (1999) Delayed neuronal loss after administration of intracerebroventricular kainic acid to preweanling rats. Dev Brain Res 112:107–116Google Scholar
  78. 78.
    Humphrey WM, Dong H, Csernansky CA, Csernansky JG (2002) Immediate and delayed hippocampal neuronal loss induced by kainic acid during early postnatal development in the rat. Dev Brain Res 137:1–12Google Scholar
  79. 79.
    Dong H, Csernansky CA, Chu Y, Csernansky JG (2003) Intracerebroventricular kainic acid administration to neonatal rats alters interneuron development in the hippocampus. Dev Brain Res 145:81–92Google Scholar
  80. 80.
    Dong H, Csernansky CA, Goico B, Csernansky JG (2003) Hippocampal neurogenesis follows kainic acid-induced apoptosis in neonatal rats. J Neurosci 23:1742–1749PubMedGoogle Scholar
  81. 81.
    Pulido OM (2008) Domoic acid toxicologic pathology: a review. Mar Drugs 6:180–219PubMedGoogle Scholar
  82. 82.
    Levin ED, Pizarro K, Pang WG, Harrison J, Ramsdell JS (2005) Persisting behavioral consequences of prenatal domoic acid exposure in rats. Neurotox Teratol 27:719–725Google Scholar
  83. 83.
    Levin ED, Pang WG, Harrison J, Williams P, Petro A, Ramsdell JS (2006) Persistent neurobehavioral effects of early postnatal domoic acid exposure in rats. Neurotoxi Teratol 28:673–680Google Scholar
  84. 84.
    Adams AL, Doucette TA, Ryan CL (2008) Altered pre-pulse inhibition in adult rats treated neonatally with domoic acid. Amino Acid 35:157–160Google Scholar
  85. 85.
    Adams AL, Doucette TA, James R, Ryan CL (2009) Persistent changes in learning and memory in rats following neonatal treatment with domoic acid. Physiol Behav 96:505–512PubMedGoogle Scholar
  86. 86.
    Doucette TA, Ryan CL, Tasker RA (2007) Gender-based changes in cognition and emotionality in a new rat model of epilepsy. Amino Acid 32:317–322Google Scholar
  87. 87.
    Burt MA, Ryan CL, Doucette TA (2008) Altered responses to novelty and drug reinforcement in adult rats treated neonatally with domoic acid. Physiol Behav 93:327–336PubMedGoogle Scholar
  88. 88.
    Burt MA, Ryan CL, Doucette TA (2008) Low dose domoic acid in neonatal rats abolishes nicotine induced place preference during late adolescence. Amino Acid 35:247–24989Google Scholar
  89. 89.
    Ryan CL, Robbins MA, Smith MT, Gallant IC, Adams-Marriott AL, Doucette TA (2011) Altered social interaction in adult rats following neonatal treatment with domoic acid. Physiol Behav 102:291–295PubMedGoogle Scholar
  90. 90.
    Autism Society Canada (2012) http://www.autismsocietycanada.ca/ Accessed 24 Feb 2012
  91. 91.
    Iwata K, Matsuzaki H, Takei N, Manabe T, Mori N (2010) Animal models of autism: an epigenetic and environmental viewpoint. J Cent Nerv Syst Dis 2:37–44Google Scholar
  92. 92.
    Ganz ML (2007) The lifetime distribution of the incremental societal costs of autism. Arch Pediatric Adolescent Med 161:343–349Google Scholar
  93. 93.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. In: Section A 09 - autism spectrum disorder, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  94. 94.
    Konstantareas MM, Hewitt T (2001) Autistic disorder and Schizophrenia: diagnostic overlaps. J Autism Dev Disord 31:19–28PubMedGoogle Scholar
  95. 95.
    Perry W, Minassian A, Lopez B, Maron L, Lincoln A (2007) Sensorimotor gating deficits in adults with autism. Biol Psychiatry 61:482–486PubMedGoogle Scholar
  96. 96.
    Macneil LK, Mostofsky SH (2012) Specificity of dyspraxia in children with autism. Neuropsychology 26:165–171Google Scholar
  97. 97.
    Maski KP, Jeste SS, Spence SJ (2011) Common neurological co-morbidities in autism spectrum disorders. Curr Opin Pediatr 23:609–615PubMedGoogle Scholar
  98. 98.
    Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatr 47:921–929Google Scholar
  99. 99.
    Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, Tager-Flusberg H, Lainhart JE (2006) Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Dis 36:849–861Google Scholar
  100. 100.
    Mukaddes NM, Hergűner S, Tanidir C (2010) Psychiatric disorders in individuals with high-functioning autism and Asperger’s disorder: similarities and differences. World J Biol Psychiatr 11:964–971Google Scholar
  101. 101.
    Skokauskas N, Gallagher L (2010) Psychosis, affective disorders and anxiety in autistic spectrum disorder: prevalence and nosological considerations. Psychopathology 43:8–16PubMedGoogle Scholar
  102. 102.
    Charnsil C, Sriapai P (2011) Attention deficit hyperactivity symptoms in children with autistic disorder: a cross-sectional descriptive study. J Med Assoc Thail 94:231–234Google Scholar
  103. 103.
    Sipes M, Matson JL, Horovitz M, Shoemaker M (2011) The relationship between autism spectrum disorders and symptoms of conduct problems: the moderating effect of communication. Dev Neurorehab 14:54–59Google Scholar
  104. 104.
    Clarke DF, Roberts W, Daraksan M, Dupuis A, McCabe J, Wood H, Snead OC 3rd, Weiss SK (2005) The prevalence of autistic spectrum disorder in children surveyed in a tertiary care epilepsy clinic. Epilepsia 46:1970–1977PubMedGoogle Scholar
  105. 105.
    Tuchman R, Rapin I (2002) Epilepsy in autism. Lancet Neurol 1:352–358PubMedGoogle Scholar
  106. 106.
    Tuchman R, Moshé SL, Rapin I (2009) Convulsing toward the pathophysiology of autism. Brain Dev 31:95–103PubMedGoogle Scholar
  107. 107.
    Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P, Mottron L, Cohen D (2008) Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol Psychiatry 64:577–582PubMedGoogle Scholar
  108. 108.
    Brooks-Kayal A (2010) Epilepsy and autism spectrum disorders: are there common developmental mechanisms? Brain Dev 32:731–738PubMedGoogle Scholar
  109. 109.
    Nazeer A (2011) Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatr Clin North Am 58:85–97PubMedGoogle Scholar
  110. 110.
    Patterson PH (2011) Modeling autistic features in animals. Pediatr Res 69:34R–40RPubMedGoogle Scholar
  111. 111.
    Geschwind DH (2011) Genetics of autism spectrum disorders. Trends in Cognit Sci 15:409–416Google Scholar
  112. 112.
    Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH (2012) Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun 26:607–616Google Scholar
  113. 113.
    Dufour-Rainfray D, Vourc’h P, Tourlet S, Guilloteau D, Chalon S, Andres CR (2011) Fetal exposure to teratogens: evidence of genes involved in autism. Neurosci Biobehav Rev 35:1254–1265PubMedGoogle Scholar
  114. 114.
    Dufour-Rainfray D, Vourc’h P, Le Guisquet AM, Garreau L, Ternant D, Bodard S, Jaumain E, Gulhan Z, Belzung C, Andres CR, Chalon S, Guilloteau D (2010) Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett 470:55–59PubMedGoogle Scholar
  115. 115.
    Schneider T, Roman A, Basta-Kaim A, Kubera M, Budziszewska B, Schneider K, Przewłocki R (2008) Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 33:728–740PubMedGoogle Scholar
  116. 116.
    Schneider T, Przewlocki R (2005) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30:80–89PubMedGoogle Scholar
  117. 117.
    Kim KC, Kim P, Go HS, Choi CS, Yang SI, Cheong JH, Shin CY, Ko KH (2011) The critical period of valproate exposure to induce autistic symptoms in Sprague–Dawley rats. Toxicol Lett 201:137–142PubMedGoogle Scholar
  118. 118.
    Markram K, Rinaldi T, La Mendola D, Sandi C, Markram H (2008) Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 33:901–912Google Scholar
  119. 119.
    Schneider T, Ziolkowska B, Gieryk A, Tyminska A, Przewłocki R (2007) Prenatal exposure to valproic acid disturbs the enkephalinergic system functioning, basal hedonic tone, and emotional responses in an animal model of autism. Psychopharmacology 193:547–555PubMedGoogle Scholar
  120. 120.
    Tashiro Y, Oyabu A, Imura Y, Uchida A, Narita N, Narita M (2011) Morphological abnormalities of embryonic cranial nerves after in utero exposure to valproic acid: implications for the pathogenesis of autism with multiple developmental anomalies. Int J Dev Neurosci 29:359–364PubMedGoogle Scholar
  121. 121.
    Kuwagata M, Ogawa T, Shioda S, Nagata T (2009) Observation of fetal brain in a Rat valproate-induced autism model: a developmental neurotoxicity study. Int J Dev Neurosci 27:399–405PubMedGoogle Scholar
  122. 122.
    Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772–1775PubMedGoogle Scholar
  123. 123.
    Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14:1105–1116PubMedGoogle Scholar
  124. 124.
    Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, Simpson EM, McCaffery JM, El-Husseini AE, Leavitt BR, Hayden MR (2006) Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. PNAS 103:9595–9600PubMedGoogle Scholar
  125. 125.
    Shaw CA, Banjo OC (2008) Fetal exposure of mice to cycad neurotoxins impacts postnatal behaviour. Program No. 445.25. Neuroscience Meeting Planner, Washington, DC: Society for Neuroscience. (Online)Google Scholar
  126. 126.
    Wilson JM, Khabazian I, Wong MC, Seyedalikhani A, Bains JS, Pasqualotto BA, Williams DE, Andersen RJ, Simpson RJ, Smith R, Craig UK, Kurland LT, Shaw CA (2002) Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. J Neuromol Med 1:207–222Google Scholar
  127. 127.
    Khabazian I, Bains JS, Williams DE, Cheung J, Wilson JM, Pasqualotto BA, Pelech SL, Andersen RJ, Wang YT, Liu L, Nagai A, Kim SU, Craig UK, Shaw CA (2002) Isolation of various forms of sterol β-d-glucoside from the seed of cycas circinalis: neurotoxicity and implications for ALS-PDC. J Neurochem 83:1–13Google Scholar
  128. 128.
    Tabata RC, Wilson JM, Ly P, Zwiegers P, Kwok D, Van Kampen JM, Cashman N, Shaw CA (2008) Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ASL-PDC phenotype. Neuromol Med 10:24–39Google Scholar
  129. 129.
    Barlow BK, Richfield EK, Cory-Slechta DA, Thiruchelvam M (2004) A fetal risk factor for Parkinson’s disease. Dev Neurosci 26:11–23PubMedGoogle Scholar
  130. 130.
    Fisher LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185:232–240Google Scholar
  131. 131.
    Kurland LT (1988) Amyotrophic lateral sclerosis and Parkinson’s disease complex on Guam linked to an environmental neurotoxin. Trends Neurol Sci 11:51–54Google Scholar
  132. 132.
    Whiting MG (1964) Food practices in ALS foci in Japan, the Marianas, and New Guinea. Federation Proc. Third Conference on Toxicity of Cycads 23: 1343–1345Google Scholar
  133. 133.
    Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR (2007) Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology 68:1764–1767PubMedGoogle Scholar
  134. 134.
    Shen W-B, McDowell KA, Siebert AA, Clark SM, Dugger NV, Valentino KM, Jinnah HA, Sztalryd C, Fishman PS, Shaw CA, Jafri MS, Yarowsky PJ (2010) Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann Neurol 68(6):70–80Google Scholar
  135. 135.
    Spencer PS, Hugon J, Ludolph A, Nunn PB, Ross SM, Roy DN, Schaumburg HH (1987) Discovery and partial characterization of primate motor-system toxins. CIBA Found Symp 126:221–238PubMedGoogle Scholar
  136. 136.
    Dastur DK (1964) Cycad toxicity in monkeys: clinical, pathological, and biochemical aspects. Fed Proc 23:1368–1369PubMedGoogle Scholar
  137. 137.
    Perry TL, Bergeron C, Biro AJ, Hansen S (1989) Beta-N-methylamino-l-alanine. Chronic oral administration is not neurotoxic to mice. J Neurol Sci 94:173–180PubMedGoogle Scholar
  138. 138.
    Cruz-Aguado R, Winkler D, Shaw CA (2006) Lack of behavioral and neuropathological effects of dietary b-methylaminoalanine (BMAA) in mice. Pharmacol Biochem Behav 84:294–299PubMedGoogle Scholar
  139. 139.
    Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Ann Rev Genomic Hum Genet 12:301–325Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Amber L. Marriott
    • 1
  • Daphne A. Gill
    • 1
  • Christopher A. Shaw
    • 2
  • R. Andrew Tasker
    • 1
  1. 1.Department of Biomedical SciencesUniversity of Prince Edward IslandCharlottetownCanada
  2. 2.Departments of Ophthalmology and Visual Sciences and Experimental Medicine and Graduate Program in NeurosciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations